D
D. J. Perry
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 28
Citations - 2085
D. J. Perry is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 20, co-authored 28 publications receiving 1912 citations. Previous affiliations of D. J. Perry include University College London.
Papers
More filters
Journal ArticleDOI
The rare coagulation disorders – review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation
Paula H. B. Bolton-Maggs,D. J. Perry,Elizabeth Chalmers,L. A. Parapia,Jonathan T. Wilde,Michael Williams,Peter William Collins,Steve Kitchen,Gerry Dolan,Andrew D Mumford +9 more
TL;DR: This review summarizes the current literature for disorders of fibrinogen, and deficiencies of prothrombin, factor V, FV’+ VIII, FVII, FX, the combined vitamin K‐dependent factors, FXI and FXIII with a section on Ehlers‐Danlos Syndrome.
Journal ArticleDOI
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell,K. John Pasi,Margaret V. Ragni,Margareth C. Ozelo,Leonard A. Valentino,Johnny Mahlangu,Neil C. Josephson,D. J. Perry,Marilyn J. Manco-Johnson,Shashikant Apte,Ross I. Baker,Godfrey Chi-Fung Chan,Nicolas Novitzky,Raymond S.M. Wong,Snejana Krassova,G. Allen,Haiyan Jiang,Alison Innes,Shuanglian Li,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Karen Nugent,Gloria Vigliani,Aoife Brennan,Alvin Luk,Glenn F. Pierce +27 more
TL;DR: Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B, mostly consistent with those expected in the general population of patients withhemophilia.
Journal ArticleDOI
Congenital factor x deficiency: spectrum of bleeding symptoms in 32 iranian patients
TL;DR: It is demonstrated that the bleeding tendency of factor X deficiency is severe and correlates with factor levels.
Journal ArticleDOI
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies
Ernest Turro,Daniel Greene,Daniel Greene,Anouck Wijgaerts,Chantal Thys,Claire Lentaigne,Claire Lentaigne,Tadbir K. Bariana,Tadbir K. Bariana,Sarah K Westbury,Anne M. Kelly,Anne M. Kelly,Dominik Selleslag,Jonathan Stephens,Jonathan Stephens,Jonathan Stephens,Sofia Papadia,Sofia Papadia,Ilenia Simeoni,Ilenia Simeoni,Christopher J. Penkett,Christopher J. Penkett,Sofie Ashford,Sofie Ashford,Antony P. Attwood,Antony P. Attwood,Antony P. Attwood,Steve Austin,Tamam Bakchoul,Peter William Collins,Sri V V Deevi,Sri V V Deevi,Rémi Favier,Myrto Kostadima,Myrto Kostadima,Michele P. Lambert,Michele P. Lambert,Mary Mathias,Carolyn M. Millar,Carolyn M. Millar,Kathelijne Peerlinck,D. J. Perry,Sol Schulman,Deborah Whitehorn,Deborah Whitehorn,Christine Wittevrongel,Marc De Maeyer,Augusto Rendon,Keith Gomez,Keith Gomez,Wendy N. Erber,Andrew D Mumford,Paquita Nurden,Kathleen Stirrups,Kathleen Stirrups,John Bradley,John Bradley,F. Lucy Raymond,F. Lucy Raymond,Michael Laffan,Michael Laffan,Chris Van Geet,Sylvia Richardson,Kathleen Freson,Willem H. Ouwehand +64 more
TL;DR: In patients with myelofibrosis, this SRC mutation was associated with increased outgrowth of myeloid and megakaryocyte colonies, with abnormal platelet production, which could be rescued by SRC kinase inhibition, which may be important for understanding the severe bleeding in cancer patients treated with Src family kinase inhibitors.
Journal ArticleDOI
Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders
Sarah K Westbury,Ernest Turro,Ernest Turro,Daniel Greene,Daniel Greene,Claire Lentaigne,Claire Lentaigne,Anne M. Kelly,Anne M. Kelly,Tadbir K. Bariana,Tadbir K. Bariana,Ilenia Simeoni,Ilenia Simeoni,Xavier Pillois,Antony P. Attwood,Antony P. Attwood,Steve Austin,Sjoert B. G. Jansen,Sjoert B. G. Jansen,Tamam Bakchoul,Abi Crisp-Hihn,Abi Crisp-Hihn,Wendy N. Erber,Rémi Favier,Nicola Foad,Nicola Foad,Michael Gattens,Jennifer Jolley,Jennifer Jolley,Ri Liesner,Stuart Meacham,Stuart Meacham,Carolyn M. Millar,Carolyn M. Millar,Alan T. Nurden,Kathelijne Peerlinck,D. J. Perry,Pawan Poudel,Pawan Poudel,Sol Schulman,Harald Schulze,Jonathan Stephens,Jonathan Stephens,Bruce Furie,Peter N. Robinson,Peter N. Robinson,Peter N. Robinson,Chris Van Geet,Augusto Rendon,Augusto Rendon,Keith Gomez,Michael Laffan,Michele P. Lambert,Michele P. Lambert,Paquita Nurden,Willem H. Ouwehand,Willem H. Ouwehand,Willem H. Ouwehand,Sylvia Richardson,Andrew D Mumford,Kathleen Freson +60 more
TL;DR: These findings validate the novel HPO-based phenotype clustering methodology for known BPD, thus providing a new discovery tool for BPD of unknown genetic basis.